Antidepressant effect in older depressed patients: the lessons of two agomelatine trials
| Autor: | Reinhard Heun, Christian de Bodinat, Patrice Boyer, Guy M. Goodwin, Pierre Thomas, F. Picarel-Blanchot |
|---|---|
| Přispěvatelé: | Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab) |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Internationality Placebo law.invention 03 medical and health sciences [SCCO]Cognitive science 0302 clinical medicine Randomized controlled trial Older patients Double-Blind Method law Internal medicine Acetamides Medicine Agomelatine Humans Hypnotics and Sedatives Pharmacology (medical) 10. No inequality Depression (differential diagnoses) Aged Depressive Disorder Major business.industry Assay sensitivity Middle Aged Antidepressive Agents 030227 psychiatry 3. Good health Clinical trial Psychiatry and Mental health Treatment Outcome Antidepressant Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | International Clinical Psychopharmacology International Clinical Psychopharmacology, 2017, International Clinical Psychopharmacology, 32 (4), pp.184-194. ⟨10.1097/YIC.0000000000000174⟩ |
| ISSN: | 1473-5857 |
| DOI: | 10.1097/YIC.0000000000000174⟩ |
| Popis: | The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response. The increased demands on investigators in study 2 appear to have reduced the placebo effect and showed a robust benefit of agomelatine. The two agomelatine studies offer the opportunity to discuss hypotheses that have been raised to explain the low level of response of older patients to available antidepressants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|